Interleukin 6

Interleukin-6 (IL-6) -174G/C genomic polymorphism contribution to the risk of coronary artery disease in a Chinese population

L. Mao, Geng, G. Y., Han, W. J., Zhao, M. H., Wu, L., Liu, H. L., Mao, L., Geng, G. Y., Han, W. J., Zhao, M. H., Wu, L., and Liu, H. L., Interleukin-6 (IL-6) -174G/C genomic polymorphism contribution to the risk of coronary artery disease in a Chinese population, vol. 15, p. -, 2016.

To investigate the role of IL-6 polymorphism (-174G/C and -572C/G) in the development of coronary artery disease (CAD), CAD patients (224) and control subjects (260) were recruited between January 2012 and December 2014. Genotyping at IL-6 -174G/C and -572C/G was conducted via polymerase chain reaction coupled to restriction fragment length polymorphism. Results indicated that several disease risk factors were significantly higher in CAD patients as compared to the control subjects.

Association of the IL6 polymorphism rs1800796 with cancer risk: a meta-analysis

Y. Du, Gao, L., Zhang, K., and Wang, J., Association of the IL6 polymorphism rs1800796 with cancer risk: a meta-analysis, vol. 14, pp. 13236-13246, 2015.

The human IL6 [interleukin 6 (interferon, beta 2)] gene encodes IL-6, a cytokine which not only plays regulatory roles in inflammation, but may be also involved in the progression of cancer. Rs1800796 is a single nucleotide polymorphism (SNP) in the promoter region of IL6, and is associated with IL-6 production. A number of studies have been carried out to determine whether this SNP is associated with cancer risk. However, the results are inconsistent due to small sample sizes of individual studies and limited statistical power.

Subscribe to Interleukin 6